medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 3

<< Back Next >>

Med Int Mex 2021; 37 (3)

Current treatment of fatty liver of nonalcoholic origin

Córdova-Pluma VH, Vega-López CA, Ortega-Chavarría MJ

Language: Spanish
References: 28
Page: 396-402
PDF size: 217.30 Kb.


ABSTRACT

Non-alcoholic fatty liver has emerged as a world level health problem, being strongly linked to obesity, which is considered the metabolic syndrome hepatic component. At worldwide level an incidence of up to 25.24% is reported with the highest indexes in Middle East and South America, the data in our country reveal its presence up to 17.1% of asymptomatic patients. Non-alcoholic fatty liver is due to a complex interaction between genetic and environmental factors, which result in a metabolic imbalance and cause a cardiovascular comorbidity. In most cases the diagnosis tends to be incidental, with the hepatic biopsy the golden standard for its confirmation. The changes in lifestyles are fundamental basis of the treatment, being the loss of weight the most important intervention, since it improves the sensitivity to insulin and reduces the metabolic and cardiovascular risks. At this time the use of pioglitazone and vitamin E is only recommended by the American Association for Liver Study in cases of liver steatosis; others, such as pentoxifylline, peptide agonistics similar to glucagon type 1 (GLP-1), obeticholic acid, elafibranor, selonsertib and cenicriviroc, are in study phase with promising results. Due to the increase in obesity cases and metabolic syndrome at world level, physician should suspect the diagnosis of nonalcoholic fatty liver and know the treatment currently available of this disease, being this the motive of the review.


REFERENCES

  1. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10 (11): 656-65. doi. 10.1038/nrgastro.2013.183.

  2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142 (7): 1592-609. doi. 10.1053/j. gastro.2012.04.001.

  3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363(14): 1341-50. doi. 10.1056/ NEJMra0912063.

  4. Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, et al. Global epidemiology of nonalcoholic fatty liver disease: metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (4): 1388-9. doi. 10.1002/ hep.28584.

  5. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, Chávez-Tapia NC, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol 2014; 13 (2): 166-78.

  6. Petta S, Gastaldelli A, Rebelos E, Bugianesi E, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci 2016; 17(12): E2082. doi. 10.3390/ijms17122082.

  7. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 2010; 12 (5): 365-83. doi. 10.1111/j.1463-1326.2009.01176.x.

  8. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313 (22): 2263-73. doi. 10.1001/ jama.2015.5370.

  9. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40 (10): 1209-22. doi. 10.1111/apt.12963.

  10. Petta S, Vanni E, Bugianesi E, Di Marco V, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35 (5): 1566-73. doi. 10.1111/ liv.12584.

  11. Delgado-Cortés HM, García-Juárez FI, García-Juares I. La enfermedad por hígado graso no alcohólico y el trabajo del internista. Rev Hosp Jua Mex 2018; 85(2): 86-93.

  12. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (1): 121-9. doi. 10.1002/hep.23276.

  13. Zhang HJ, He J, Pan LL, Ma ZM, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med 2016; 176 (8): 1074-82. doi. 10.1001/jamainternmed.2016.3202.

  14. Eslamparast T, Tandon P, Raman M. Dietary composition independent of weight loss in the management of nonalcoholic atty liver disease. Nutrients 2017; 9 (8): 800. doi. 10.3390/nu9080800.

  15. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improve hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138-43. doi. 10.1016/j.jhep.2013.02.012.

  16. Moctezuma-Velázquez C. Tratamiento actual de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2018; 83 (2): 125-133. doi. 10.1016/j.rgmx.2017.10.003.

  17. Jennison E, Patel J, Scorletti E, Byrne CD, et al. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J 2019; 95 (1124): 314-322. doi. 10.1136/ postgradmedj-2018-136316.

  18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23. doi. 10.1002/hep.25762.

  19. Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie 2017; 136: 65-74. doi. 10.1016/j.biochi. 2016.11.009.

  20. Sanyal AJ, Chalasani N, Kowdley KV, Cullough A, et al. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362:1675-85. doi. 10.1056/ NEJMoa0907929.

  21. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med 2017; 177: 633-40. doi. 10.1001/jamainternmed.2016.9607.

  22. Singh S, Khera R, Allen AM, Murad MH, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015; 62: 1417-32. doi. 10.1002/hep.27999.

  23. Schurks M, Glynn RJ, Rist PM, Tzourio C, et al. Effects of vitamin E on stroke subtypes: metaanalysis of randomised controlled trials. BMJ 2010; 341: c5702. https://doi. org/10.1136/bmj.c5702.

  24. Wyatt G. Vitamin E increases prostate cancer risk in middleaged men relative to placebo: No significant association observed with selenium, either alone or in combination with vitamin E. Evid Based Nurs 2012; 15: 90-1. doi. 10.1136/ ebnurs-2012-100551.

  25. Thondam SK, Cuthbertson DJ, Aditya BS, Macfarlane IA, et al. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocrinol Oxf 2012; 77: 635-7. doi. 10.1111/j.1365-2265.2012.04368.x.

  26. Petit JM, Cercueil JP, Loffroy R, Denimal D, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab 2017; 102: 407-15. doi. 10.1210/jc.2016-2775.

  27. Federico A, Zulli C, de Sio I, Del Prete A, et al. Focus on emerging drugs for the treatment of patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (45): 16841-57. doi. 10.3748/wjg.v20.i45.16841.

  28. Díaz Coppe-Gutiérrez A, Velázquez-Fernández D, Herrera-Hernández MF, Pantoja-Millán JP, et al. El papel de la cirugía bariátrica en el manejo de la enfermedad por hígado graso no alcohólico. Rev Hosp Jua Mex 2017; 84 (2): 83-92.




2020     |     www.medigraphic.com